

# JAMA<sup>®</sup>

The Journal of the American Medical Association

## REPORT

Tuesday, January 27, 2015

The JAMA Report Video and Multimedia Assets are available at  
[http://jama.newsmarket.com/\[jama.newsmarket.com\]](http://jama.newsmarket.com/[jama.newsmarket.com])  
 and [www.thejama-report.com](http://www.thejama-report.com)

Please call: JAMA Media Relations with any questions: (312) 464-5262

### “M-R-I TARGETED BIOPSY BETTER FOR DETECTING HIGH-RISK PROSTATE CANCER”

TEASE RUNS: 05 (doctors and patient looking at computer screen)  
 Can M-R-I technology help detect high-risk prostate cancers? That’s next.

JAMA 3966  
 TRT: 1:57  
 EMBARGO: 11a.m. (ET) Tuesday, January 27, 2015

INTRO: Prostate cancer is usually diagnosed with a standard biopsy, which randomly samples the entire prostate with the help of ultrasound. A newer, more targeted approach uses magnetic resonance imaging or M-R-I technology to help identify prostate cancer. A new study examined whether this new approach, using M-R-I, was better at detecting prostate cancer, especially higher risk tumors. Catherine Dolf has more in this week’s JAMA Report.

VIDEO	AUDIO
NATSO/FULL Runs:04	“...we’ve met many patients like you who’s tumors are hidden...”
B-ROLL Doctor talking to Ronald and showing him images of the prostate	RONALD BRISCOE IS TALKING WITH DOCTORS ABOUT HIS PROSTATE CANCER.
SOT/FULL Ronald Briscoe - Prostate Cancer Survivor Super@:08 Runs:04	“My older brother, my father had it, and also my baby brother has it.”
B-ROLL	DOCTORS FOUND HIS HIGH-RISK PROSTATE

Doctors pointing to computer screen, cu of prostate	<b>CANCER BY USING M-R-I GUIDED TECHNOLOGY.</b>
<b>NATSO/FULL</b> Runs:04 (Video covering middle of natso: cu of Ronald looking at screen)	“...MRI can tell us where tumors are hiding in the prostate, that’s not normally sampled...”
<b>B-ROLL</b> Slide showing needles in prostate	<b>THIS APPROACH IS DIFFERENT FROM A STANDARD PROSTATE BIOPSY THAT USES ULTRASOUND.</b>
<b>SOT/FULL</b> Peter A. Pinto, M.D., - National Cancer Institute, National Institutes of Health Super@:25 Runs:09	“Ultrasound insures that the needles hit the prostate but we don’t use the ultrasound to direct the needles into where the tumor may be present.”
<b>SOT/FULL</b> M. Minhaj Siddiqui, M.D., - National Cancer Institute, National Institutes of Health Super@:35 Runs:05	“We randomly try to get all the prostate sampled in hopes of catching the cancer.”
<b>B-ROLL</b> Cu of Dr. Pinto, pan to Dr. Siddiqui dissolve to three doctors looking at the computer screen	<b>DOCTORS PETER PINTO AND MINHAIJ (Min-ahj) SIDDIQUI (Sih-dee-Key) FROM THE NATIONAL CANCER INSTITUTE, NATIONAL INSTITUTES OF HEALTH ALONG WITH THEIR CO-AUTHORS LOOKED AT MORE THAN A THOUSAND MEN WITH ELEVATED P-S-A LEVELS. THESE MEN UNDERWENT BOTH AN M-R-I GUIDED TARGETED BIOPSY AND ALSO THE TRADITIONAL STANDARD BIOPSY USING ULTRASOUND ALONE. THE RESULTS OF BOTH BIOPSIES WERE THEN COMPARED.</b>
<b>SOT/FULL</b> Peter A. Pinto, M.D., - National Cancer Institute, National Institutes of Health Super@1:02 Runs:13 (Video covering 1 <sup>st</sup> part of bite: slide of MRI biopsy)	“The targeted MR guided biopsy had a 30 percent increase in detection of high-risk prostate cancer as compared to the traditional biopsies performed today.”
<b>GXF FULL</b> JAMA COVER	<b>THE STUDY APPEARS IN JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.</b>
<b>SOT/FULL</b> Peter A. Pinto, M.D., - National Cancer Institute, National Institutes of Health Super@1:14 Runs:12	“Low risk cancers that are felt to be over diagnosed and over treated were actually detected 17 percent less in a targeted biopsy.”

<b>B-ROLL</b> Doctors walking down hallway	<b>WHILE THE RESULTS OF THIS STUDY ARE PRELIMINARY, ADDITIONAL RESEARCH IS STILL NEEDED TO UNDERSTAND HOW THIS NEW TECHNOLOGY MIGHT BE USED IN THE FUTURE.</b>
<b>SOT/FULL</b> M. Minhaj Siddiqui, M.D., - National Cancer Institute, National Institutes of Health Super@1:34 Runs:18 (Video covering middle of bite: Dr. Siddiqui pointing to computer)	<b>“The benefit of doing that is that we maximize our ability to detect the high risk cancers that matter and also potentially avoid the harm of detecting cancer which is clinically insignificant and unlikely to cause problems for the patient.”</b>
<b>SOT/FULL</b> Ronald Briscoe - Prostate Cancer Survivor Super@1:51 Runs:04	<b>“If you catch it early and get it done, taken care of, you get to live a longer life.”</b>
<b>B-ROLL</b> Ronald shaking hands with Dr. Pinto	<b>CATHERINE DOLF, THE JAMA REPORT.</b>

**TAG: BOTH THE TARGETED AND STANDARD PROSTATE BIOPSY CAN BE DONE IN THE OUT PATIENT SETTING.**

Please see the complete study for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

**TO CONTACT: Dr. Peter Pinto call: Aleea Khan at (301) 496-6641 or Dr. Minhaj Siddiqui call: Karen Warmkessel at (410) 328-8919**

**ADDITIONAL SOUNDBITES:**

**Peter A. Pinto, M.D., - National Cancer Institute, National Institutes of Health**

**QUOTE 1 Runs:13**

**“For men that have a high-risk cancer that may not be easily found with the traditional random biopsy, this MRI directed technology allows us to uncover those hidden tumors.”**

**M. Minhaj Siddiqui, M.D., -**

**QUOTE 1 Runs:14**

**“The biopsy approach that gave the most clinical utility in terms of maximizing benefit and reducing harm in appropriate decision making for treatment of prostate cancer was the targeted approach.”**

